Clinical Trial

NASH/Fatty Liver Clinical Trial 2016-023

[LCID Study Number: 2016-023]

A Phase 3, Double Blind Randomized, Long Term Placebo-Controlled Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (REGENERATE Study)

The purpose of this study is to evaluate the safety and efficacy of Obeticholic Acid in subjects with Nonalcoholic Steatohepatitis (an advanced form of Fatty Liver Disease).

Disease/Condition: Nonalcoholic Steatohepatitis (NASH)/Fatty Liver Clinical

Department: Transplantation & Hepatobiliary Diseases

Status: Active, Not Recruiting

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email:

Clinical Trial Details

View NCT ID 02548351 on

Protocol #: 2016-023

Principal Investigator(s): Fredric D. Gordon

Study Coordinator(s): Ali Brien

Trial Phase: Sponsor Initiated Study Phase 3